Genetics as predictive marker for consolidation therapy with high-dose cytarabine in acute myeloid leukemia

• Richard F. Schlenk

Affiliations

Richard F. Schlenk

Department of Internal Medicine V, Heidelberg University Hospital; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg